Login to Your Account



Dad goes nuclear: FDA support for Nanosmart not hard 'cell' in cancer

By Randy Osborne
Staff Writer

Thursday, July 30, 2015
Winning orphan drug status for a second preclinical cancer therapy is "small but important progress" for Nanosmart Pharmaceuticals Inc., President James Smith told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription